Synta Pharmaceuticals narrows Q4 loss, beats the Street
Biopharmaceutical company Synta Pharmaceuticals Corp. (Nasdaq: SNTA) reported this morning that its fourth-quarter net loss narrowed from a year ago and clocked in better than the expected consensus on Wall Street.
For detailed price information and recent news stories about Synta Pharmaceuticals, click SNTA.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
